Jani Seitsonen

Jani Seitsonen serves as a Senior Scientist and Staff Scientist at OtaNano, Aalto University, Espoo, Finland. With over 100 research publications spanning 2013-2025, his work centers on nanotechnology and material science, specializing in peptide-based self-assembly, nanostructure characterization, and functional nanomaterial development for biomedical and environmental applications.

His core research integrates material science, nanotechnology, and peptide chemistry to investigate lipopeptide nanostructures, antimicrobial systems, and nanomaterials for drug delivery. Key methodologies include transmission electron microscopy and small-angle X-ray scattering, enabling precise analysis of nanoparticle formation, surface dynamics, and molecular interactions in contexts ranging from wound healing to cancer therapy. This interdisciplinary approach bridges chemistry, biophysics, and biomedical engineering to create responsive nanosystems.

Recent publications (2024-2025) demonstrate a pronounced shift toward biomedical applications, including antimicrobial peptide design, self-adjuvanting cancer vaccines, and tumor-targeting microbubbles, while maintaining strong environmental applications like pesticide detection. These works consistently leverage peptide amphiphilicity and chirality to engineer nanostructures with tunable disassembly properties, highlighting his focus on functional precision at the molecular level.

No scientific awards were mentioned in the available information.

There is no available information regarding students advised or research grants obtained by Dr. Seitsonen.

As a core researcher at OtaNano—a national micro- and nanotechnology infrastructure—Seitsonen operates within interdisciplinary teams specializing in nanocharacterization and biomaterial synthesis. His collaborations span international institutions including the University of Reading and University of Helsinki, with recent work involving hydrophobin engineering, peptide conjugation, and microbubble development for targeted therapeutic delivery.